Biology subjects

Balduini, A.

Publications and source records attributed to Balduini, A..

4 recordsLinked to original sources

bioRxiv2026

CRISPR/Cas9-mediated deletion of Shp1 and Shp2 reveals distinct roles in human megakaryopoiesis and proplatelet formation

The non-receptor protein-tyrosine phosphatases Shp1 (PTPN6) and Shp2 (PTPN11) play critical roles in hematopoietic signaling networks, yet their specific functions in human megakaryopoiesis and thrombopoiesis remain incompletely understood. While Shp2 is recognized in murine models as a positive regulator of thrombopoietin (Tpo)-mediated signaling through the Ras/MAPK and PI3K/AKT pathways, Shp1 has been implicated in RhoA-dependent cytoskeletal remodeling. However, the extent to which these roles translate to human megakaryocyte (MK) development and platelet production is not known. In this study, we systematically investigated the contributions of Shp1 and Shp2 to human MK development and function using CRISPR/Cas9-mediated gene deletion of PTPN6 and PTPN11 in CD34+ hematopoietic stem and progenitor cells (HSPCs), combined with pharmacological inhibition of Shp2 using the structurally-distinct allosteric inhibitors SHP099 and RMC-4550. Efficient gene editing of PTPN6 and PTPN11 resulted in efficient ablation of Shp1 and Shp2 in CD34+ HSPC-derived MKs. Genetic deletion or pharmacological inhibition of Shp2 markedly impaired MK proliferation, polyploidization, maturation, and proplatelet formation, whereas loss of Shp1 expression did not. Further, Shp2 inhibition significantly reduced platelet production in a 3-dimensional human bone marrow tissue model. Deletion and inhibition of Shp2 abrogated Tpo-induced ERK1/2 and AKT phosphorylation, confirming its essential role in Mpl receptor signaling. These findings demonstrate the distinct functional roles of Shp1 and Shp2 in MKs and establish Shp2 as a critical positive regulator of Mpl- mediated megakaryopoiesis and thrombopoiesis. Key PointsO_LIEfficient deletion of Shp1 and Shp2 in human CD34 progenitor cell-derived MKs using CRISPR/Cas9. C_LIO_LILoss of Shp2 expression impairs thrombopoietin-induced human MK maturation, proplatelet formation and Mpl signaling. C_LI

cell biology↗

bioRxiv2026

A bioprinted silk marrow niche reveals mechanical regulation of human megakaryopoiesis under genotoxic stress

Hematopoietic stem and progenitor cells (HSPCs) reside in a mechanically distinct bone marrow niche, yet how niche biomechanics shape genome stability and stress responses has been difficult to test because conventional two-dimensional (2D) culture lacks marrow viscoelasticity and uses surfaces that activate platelets, confounding hematopoietic readouts. Here, we show that this methodological gap has masked a basic principle: the marrow niche actively constrains genotoxic stress signaling in HSPCs, and 2D culture systematically overstates DNA damage and impairs differentiation in vitro. We engineered silk fibroin, a biologically inert biomaterial that does not activate platelets and recapitulates marrow viscoelasticity, into SilkInk, a 3D-bioprintable bioink, and used it to reconstruct a biomimetic marrow microenvironment. HSPCs encapsulated in SilkInk preserved clonogenic potential and multilineage differentiation, whereas 2D-cultured HSPCs activated cytoskeletal-tension and genome-surveillance programs characteristic of chronic stress, including pathways related to replication stress, DNA damage response, and redox stress. Cell phenotyping and single-cell RNA sequencing during megakaryopoiesis revealed that SilkInk supported coordinated endomitotic progression and terminal maturation, with progression from CD34+CD61-CD41-CD42b- progenitors to CD34-CD61+CD41+CD42b+ megakaryocytes, including increased 8N and >16N populations, whereas 2D culture and conventional 3D hydrogels sustained DNA damage signaling and impaired thrombopoiesis. The same hierarchy held under cytotoxic challenge, as 5-fluorouracil amplified DNA damage and crippled platelet output in 2D, whereas SilkInk-encapsulated HSPCs maintained differentiation, mirroring native marrow resilience. These findings reposition niche mechanics as an active determinant of hematopoietic genome stability and establish SilkInk as a physiologically faithful platform for studying hematopoiesis and predicting marrow responses to chemotherapy.

Cell Biology↗

bioRxiv2025

Identification of the role of SEL1L in platelet function through a multi-species genetic investigation

SEL1L is a well-known protein in the endoplasmic reticulum associated degradation (ERAD) pathway. While it is known to be expressed in platelets, SEL1L has never been shown to play an active role. Here we find evidence that SEL1L regulates platelet function. We first identified SEL1L through the study of Atypical Equine Thrombasthenia (AET), an autosomal recessive platelet disorder found in Thoroughbred horses. A missense variant in SEL1L (c.1810A>G p.Ile604Val) was found in AET-affected horses, which we show is associated with decreased protein expression. SEL1L is intracellular in equine platelets and localizes to the surface upon activation with thrombin. Platelets from homozygous horses exhibit significant decreases in spreading on immobilized collagen. Human megakaryocytes were found to have two SEL1L protein isoforms that increase in expression during megakaryopoiesis, although only one is delivered to mature platelets. Studies using inducible mouse and constitutive zebrafish knockouts demonstrate that SEL1L is necessary for efficient platelet or thrombocyte (fish equivalent) adhesion to sites of endothelial injury. These data reveal a previously undescribed and conserved role for the ERAD pathway in the etiology of AET and platelet function, which may play a role in human platelet disorders as well. Brief SummaryUsing a multi-species approach, SEL1L was determined to have a role in platelet function, specifically in helping platelets properly adhere to sites of injury,

genetics↗

bioRxiv2022

ANKRD26 is a new regulator of type I cytokine receptor signaling in normal and pathological hematopoiesis

Sustained ANKRD26 expression associated with germline ANKRD26 mutations causes Thrombocytopenia 2 (THC2), an inherited platelet disorder associated with leukemia predisposition. Some of those patients present also erythrocytosis and/or leukocytosis. Using multiple human-relevant in vitro models (cell lines, primary patient cells and patient-derived iPSCs) we demonstrate for the first time that ANKRD26 is expressed during the early steps of erythroid, megakaryocyte and granulocyte differentiation, and is necessary for progenitor proliferation. As differentiation progresses, ANKRD26 expression is progressively silenced, to complete the cellular maturation of the three myeloid lineages. In primary cells, abnormal ANKRD26 expression in committed progenitors directly impacts the proliferation/differentiation balance for these three cell types. We show that ANKRD26 interacts with and crucially modulates the activity of MPL, EPOR and G-CSFR, three homodimeric type I cytokine receptors that regulate blood cell production. Higher than normal levels of ANKRD26 prevent the receptor internalization, which leads to increased signaling and cytokine hypersensitivity. Altogether these findings show that ANKRD26 overexpression or the absence of its silencing during differentiation are responsible for myeloid blood cell abnormalities in THC2 patients.

cell biology↗